Charles Joseph Magolske
Directeur Général chez Artin Bioscience, Inc.
Profil
Charles Joseph Magolske is currently the Chief Executive Officer & Director at Artin Bioscience, Inc. He previously worked as an Independent Non-Executive Director at Titagarh Rail Systems Ltd., Vice President-Marketing at Trinity Industries, Inc., Vice President-Corporate Development & Marketing at HudBay Arizona Corp., Vice President-Corporate Development at Arizona Mining, Inc., Vice President-Business Development & Strategy at FreightCar America, Inc., and Head-Business Development at Oroco Resource Corp.
Magolske holds an MBA degree from the University of Virginia Darden School of Business.
Postes actifs de Charles Joseph Magolske
| Sociétés | Poste | Début |
|---|---|---|
Artin Bioscience, Inc.
 Artin Bioscience, Inc. BiotechnologyHealth Technology Artin Bioscience, Inc. is an American US-based company that is pioneering precision therapeutics to treat serious diseases triggered by intestinal inflammation. The company is creating a new class of transformative precision therapeutics that target and block the root causes of diverse diseases. Artin Bioscience is backed by highly respected investors and governed by a prestigious board of directors with broad industry experience. The company uses multi-modality approaches to correct intestinal dysbiosis by neutralizing the core triggers of the inflammatory process. Artin Bioscience's proprietary drug discovery platform identifies and characterizes microbial drivers of disease within precise patient subsets in certain cancers and gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases. The company's world-class biobanking program collects proprietary samples and clinical data from patients and healthy controls to enable critical research into disease mechanisms and aid the development of potential treatments. | Directeur Général | - |
Anciens postes connus de Charles Joseph Magolske
| Sociétés | Poste | Fin |
|---|---|---|
| TITAGARH RAIL SYSTEMS LIMITED | Directeur/Membre du Conseil | 24/12/2012 |
| FREIGHTCAR AMERICA, INC. | Corporate Officer/Principal | 15/12/2009 |
| TRINITY INDUSTRIES, INC. | Sales & Marketing | 01/01/2002 |
| OROCO RESOURCE CORP. | Corporate Officer/Principal | - |
| AUGUSTA RESOURCE CORP. | Sales & Marketing | - |
Formation de Charles Joseph Magolske
| University of Virginia Darden School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| TRINITY INDUSTRIES, INC. | Producer Manufacturing |
| FREIGHTCAR AMERICA, INC. | Producer Manufacturing |
| OROCO RESOURCE CORP. | Non-Energy Minerals |
| TITAGARH RAIL SYSTEMS LIMITED | Producer Manufacturing |
| Entreprise privées | 3 |
|---|---|
HudBay Arizona Corp.
 HudBay Arizona Corp. Other Metals/MineralsNon-Energy Minerals HudBay Arizona Corp. engaged in the exploration and development of mineral properties. The company was founded on January 14, 1937 and is headquartered in Vancouver, Canada. | Non-Energy Minerals |
Arizona Mining, Inc.
 Arizona Mining, Inc. Precious MetalsNon-Energy Minerals Arizona Mining, Inc. engaged in the exploration and development of silver, zinc and lead. The firm focuses on the Hermosa Project, which is located in Santa Cruz County, Arizona. Arizona Mining was founded on January 20, 1975 and was headquartered in Vancouver, Canada. | Non-Energy Minerals |
Artin Bioscience, Inc.
Artin Bioscience, Inc. BiotechnologyHealth Technology Artin Bioscience, Inc. is an American US-based company that is pioneering precision therapeutics to treat serious diseases triggered by intestinal inflammation. The company is creating a new class of transformative precision therapeutics that target and block the root causes of diverse diseases. Artin Bioscience is backed by highly respected investors and governed by a prestigious board of directors with broad industry experience. The company uses multi-modality approaches to correct intestinal dysbiosis by neutralizing the core triggers of the inflammatory process. Artin Bioscience's proprietary drug discovery platform identifies and characterizes microbial drivers of disease within precise patient subsets in certain cancers and gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases. The company's world-class biobanking program collects proprietary samples and clinical data from patients and healthy controls to enable critical research into disease mechanisms and aid the development of potential treatments. | Health Technology |